Fortis Healthcare · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
CGHS/ECHS chemotherapy drug pricing mechanism mandating 30% discount on MRP has significantly impacted oncology revenue growth, reducing it from ~27% to ~10-12%. This disproportionately affected hospitals with large government scheme beneficiary bases (Punjab, Jaipur, Delhi NCR).
Management indicated Glen Eagles hospitals (under O&M) are not yet fully stabilized and may take another 2-4 quarters to reach Fortis portfolio standards. Currently generating ~INR 6 crore management fee per quarter.
Analyst raised concern about Agilus growing at 10% while industry peers grow at 15%, potentially indicating competitive weakness despite new leadership. Management acknowledged muted growth period due to brand transition but committed to reviving performance.
Net debt increased to INR 2,233 crore (1.01x EBITDA ratio vs 0.92x YoY) primarily due to prior year acquisitions, increasing financial leverage risk in a rising interest rate environment.
